Treatment With Eribulin in Metastatic Breast Cancer

HALAVEN™ (eribulin mesylate)- metastatic breast cancerПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Dr. Sara Tolaney on Eribulin Plus Pembrolizumab for Metastatic Triple-Negative Breast CancerПодробнее

Atezolizumab, Cobimetinib, and Eribulin in Patients With Metastatic Inflammatory Breast CancerПодробнее

Breast Cancer Diaries: (#14) Starting Eribulin & getting home [Cycle 1, Day 1]Подробнее

Gut microbiome signatures correlate with OS in pts receiving eribulin +/- pembro for HR+ mBCПодробнее

Survival Outcomes With Balixafortide Plus Eribulin for Patients With HER2-Metastatic Breast CancerПодробнее

Metastatic Breast Cancer | 2022 OneOncology ConferenceПодробнее

Is endometriosis curable?Подробнее

Dr. Timothy Pluard on Balixafortide Plus Eribulin for Metastatic Breast CancerПодробнее

Patient Selection for Eribulin in Breast CancerПодробнее

Eribulin’s Role in Triple-Negative Breast CancerПодробнее

Eribulin is effective in pretreated advanced breast cancer patientsПодробнее

Recent data on eribulin in metastatic breast cancer patients from SABCSПодробнее

Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumabПодробнее

Eribulin in Metastatic TNBC: Real-World DataПодробнее

SABCS 2017 – Giampolo BianchiniПодробнее

Eribulin exhibits potent antiproliferative activities against a variety of human cancer cell typesПодробнее

The role of chemotherapy in the treatment of metastatic breast cancer patientsПодробнее

Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancerПодробнее